pandayu

Recommend Chinese medical innovation assets to help you enter the Chinese market

[pandayu @pandayu]

Is Hong Kong reaffirming its position as the ultimate global hub for healthcare capital?

[pandayu @pandayu]

Is the China Biopharma IPO boom a sustainable investment or a recipe for disaster?

[pandayu @pandayu]

The resilient growth of #China's biotech is more than just a trend—it's a story of deep innovation.

[pandayu @pandayu]

Has China become the new center of biopharma outsourcing innovation?

[pandayu @pandayu]

High-end interventions and AI surgical platforms aren't the future.

They're 2025's cash-fueled main stage.

Here is the financing list for #MedTech companies in 2025：

[pandayu @pandayu]

Parkinson's disease market size exceeds $10 billion ,Middle aged and young Parkinson's disease patients account for 5-10% of the total number of Parkinson's disease patients.This is a Chinese Parkinson's Disease Industry Panorama，This map breaks down 6 key tracks:

[pandayu @pandayu]

@vcbeathealth @pfizer @EliLillyandCo @AstraZeneca @sanofi @TakedaOncology @GSK @JNJInnovation @Boehringer 👍

[pandayu @pandayu]

This is a Chinese AI Healthcare Industry Panorama.
Who's the Next Global Winner?
This map breaks down 4 key tracks:

[pandayu @pandayu]

China's Telemedicine Industry Map Information System Manufacturer

[pandayu @pandayu]

𝐖𝐢𝐥𝐥 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦 𝐭𝐞𝐜𝐡 𝐨𝐫 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐞𝐱𝐞𝐜𝐮𝐭𝐢𝐨𝐧 𝐝𝐞𝐟𝐢𝐧𝐞 𝐂𝐡𝐢𝐧𝐚'𝐬 𝐁𝐬𝐀𝐛 𝐠𝐥𝐨𝐛𝐚𝐥 𝐥𝐞𝐚𝐝𝐞𝐫𝐬𝐡𝐢𝐩?

[pandayu @pandayu]

This comprehensive map of China’s BsAb landscape reveals how upstream innovation, midstream pipeline depth, and downstream multinational interest are converging to position the country as a pivotal player in next-generation therapeutics.

[pandayu @pandayu]

𝟑 𝐬𝐞𝐢𝐬𝐦𝐢𝐜 𝐬𝐡𝐢𝐟𝐭𝐬:
🔸Tetrabody platforms winning multi-target complexity.
🔸Pharma biotechs dominating Phase 3—speed kills.
🔸MNC deal frenzy—$1B+ upfronts now table stakes.

[pandayu @pandayu]

This China CAR-T Industrial Ecosystem map reveals the battle for next-gen supremacy.𝐖𝐢𝐥𝐥 𝐚𝐥𝐥𝐨𝐠𝐞𝐧𝐞𝐢𝐜 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦𝐬 𝐨𝐫 𝐦𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 𝐧𝐞𝐭𝐰𝐨𝐫𝐤𝐬 𝐮𝐧𝐥𝐨𝐜𝐤 𝐂𝐀𝐑-𝐓'𝐬 𝐭𝐫𝐢𝐥𝐥𝐢𝐨𝐧-𝐝𝐨𝐥𝐥𝐚𝐫 𝐩𝐨𝐭𝐞𝐧𝐭𝐢𝐚𝐥?

[pandayu @pandayu]

China's CAR-T went from 0 approvals to 3 commercial products and over 100 pipeline assets in 5 years.

[pandayu @pandayu]

@Yuhu_ai_ Best wishes, Tony!

[pandayu @pandayu]

and China's rise in power rewrites the competitive landscape.

[pandayu @pandayu]

This Small Nuclear Acid Drug Industrial Map reveals the battle for next-gen supremacy:

[pandayu @pandayu]

The global giants Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Inc., and Sarepta Therapeutics dominate the $5.2 billion market, while #Amvuttra and #Leqvio may become the next generation bestsellers. #MNC accelerates its layout,

[pandayu @pandayu]

In 2026, China's small nucleic acid drugs will usher in the first year of capital, and the listing of Suzhou Ribo Life Science Co., Ltd (Ribolia) and the acquisition of Hejia #赫吉亚 by 中国生物制药 Sino Biopharmaceutical Limited for 1.2 billion yuan will ignite the track